February 22, 2017
This aidsmap story covers a study that suggests increasing rates of sexually transmitted infections cannot easily be linked to PrEP. The study was presented in February at CROI.
PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables. Policy and program decisions are guided by data from the original randomized clinical trials as well as newer studies. There are many moving pieces and many product types.
No single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. Demonstration projects are providing information about what's available, even as research continues for additional options.
Read below to find out more about evidence from:
The 2012 US FDA decision and WHO guidance on PrEP demonstration projects were based on data from randomized controlled trials of tenofovir-based PrEP. Additional randomized trials since then have added to this evidence base.
Concluded and ongoing pilot projects, demonstration projects and open label studies offer insight into how PrEP works in the “real world”—outside of the controlled environment of a clinical trial.
There are a range of ARV-based prevention options being evaluated today. These include long-acting injectable ARVs for HIV-negative people, a vaginal ring containing the ARV dapivirine, non-TDF PrEP drugs (e.g., Maraviroc), and exploration of “multipurpose prevention technologies” that could provide contraception and protection against HIV prevention.
February 22, 2017
February 17, 2017
Aidsmap reporter Gus Cairns takes a close look at the unusual first case of non-resistant HIV acquisition while adhering to PrEP.
February 15, 2017
POZ reports on findings that oral PrEP works for women even with an abnormal vaginal microbiome. The research address concerns raised by some studies that suggested vaginal gels used as PrEP were not as effective among women with a microbial imbalance in the vagina.